검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Fast CAR T cells |
Overview Company | Shanghai Cell Therapy Group Co.,Ltd |
Overview Modality | CGT |
Overview Target | Solid Tumor |
Overview Indication | Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | We compared the rates of complete remission (CR), minimal residual disease (MRD)-negative CR, leukemia-free survival (LFS), overall survival (OS), and the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between the two groups. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia.. Treatment with chimeric antigen receptor-T (CAR-T) cells has shown promising effectiveness in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), although the process of preparing for this therapy usually takes a l… |
Toxicology CRS | 91.3% |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Fast CAR T cells |
Overview Company | Shanghai Cell Therapy Group Co.,Ltd |
Overview Modality | CGT |
Overview Target | Solid Tumor |
Overview Indication | Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | We compared the rates of complete remission (CR), minimal residual disease (MRD)-negative CR, leukemia-free survival (LFS), overall survival (OS), and the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between the two groups. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia.. Treatment with chimeric antigen receptor-T (CAR-T) cells has shown promising effectiveness in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), although the process of preparing for this therapy usually takes a l… |
Toxicology CRS | 91.3% |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교